摘要：上海，2025年6月27日–近日，药明康德宣布其南通基地（一期）荣获2025年Architizer A+Awards建筑设计大奖“工厂与仓储”类大众评选奖。该奖项充分体现了药明康德致力于为员工打造一个创新兼容、以人为本的工作环境，从而更好地为广大客户赋能，造福
转自：药明康德
上海，2025年6月27日–近日，药明康德宣布其南通基地（一期）荣获2025年Architizer A+Awards建筑设计大奖“工厂与仓储”类大众评选奖。该奖项充分体现了药明康德致力于为员工打造一个创新兼容、以人为本的工作环境，从而更好地为广大客户赋能，造福全球病患。
Architizer A+Awards是全球最具影响力的建筑奖项之一，旨在表彰那些重新定义功能和美学的突破性设计。药明康德南通基地（一期）凭借其“科技与人文共生”的前瞻性设计理念，从来自80多个国家的数千个参赛作品中脱颖而出获得奖项。
药明康德南通基地位于中国江苏省，是药明康德CRDMO平台的重要组成部分，致力于为全球客户提供全面的化学、生物学和测试解决方案。该园区由全球知名建筑设计事务所Voice Architecture Lab（VAL）整体设计，以八栋主要建筑构成两个组团，拥抱海风，顺势打造具有雕塑感的城市天际线，构建流动而开放的空间场景。Z字形展开的实验楼与研发办公区相互围合，在主干道交汇处形成具有标志性的城市界面。园区设计兼具科技与人文之美，在严谨科学的功能性分区中，创造性提供了开放、互动的空间，不仅能够满足人才、业务发展的不同需求，也为城市的发展增添一抹亮色。
南通基地体现了药明康德致力于将科技、环境可持续性和社区互动融入其运营的方方面面，这一理念也在全球多个基地得以体现。例如，公司瑞士库威基地采用了行业领先的能效标准设计，德国慕尼黑基地获得了LEED铂金认证，展现了药明康德将先进的技术设施和建筑的可持续性完美融合。
作为全球医药健康产业赋能平台，药明康德始终致力于构建一个更光明健康的未来，赋能全球客户造福病患，共同实现“让天下没有难做的药，难治的病”的伟大愿景。
关于药明康德
药明康德（股票代码：603259.SH/2359.HK）为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研究等领域。2024年，药明康德连续第四年被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的约6,000家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。
WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity
Shanghai, June 26, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is delighted to announce that its Nantong site (Phase I) has been recognized as the Popular Choice Winner in the “Factory & Warehouse” category at the 2025 Architizer A+Awards. This recognition underscores WuXi AppTec’s commitment to creating innovative, human-centric workplaces that empower employees and support customers in delivering transformative therapies for patients.
The Architizer A+Awards, recognized as one of the most influential global architecture awards, celebrates groundbreaking designs that redefine functionality and aesthetics. Competing against thousands of entries from over 80 countries, WuXi AppTec’s Nantong site stood out for its visionary design concept of 'technological-humanistic symbiosis’.
Located in Jiangsu province, China, the Nantong site is an integral part of WuXi AppTec’s CRDMO (Contract Research, Development, and Manufacturing Organization) platform, offering comprehensive chemistry, biology, and testing solutions to global customers. Designed by the acclaimed architectural firm Voice Architecture Lab (VAL), the campus integrates operational efficiency with human-centered design. Featuring eight main buildings arranged in two clusters, the site’s layout fosters collaboration and innovation while harmonizing with its natural and urban surroundings. The Z-shaped laboratory and R&D office area form a distinctive urban frontage, creating seamless connection between science, community, and environment.
The Nantong site exemplifies WuXi AppTec’s broader efforts to integrate technology, environmental sustainability, and community engagement into its operations and facilities. For instance, the Couvet site in Switzerland is built with industry-leading energy efficiency standards, while the Munich site in Germany, certified as LEED Platinum, showcases sustainable construction and advanced technical infrastructure.
As a global enabling platform for the pharmaceutical and healthcare industry, WuXi AppTec is dedicated to building a brighter, healthier future where “every drug can be made and every disease can be treated.”
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
南通园区摄影：亮点影像 HighliteImages
来源：新浪财经
